Federici AB.
Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders.
Semin Hematol. 2006 Jan;43(1 Suppl 1):S48-58.

Kunicki TJ, Baronciani L, Canciani MT, Gianniello F, Head SR, Mondala TS, Salomon DR, Federici AB.
An association of candidate gene haplotypes and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigrees.
J Thromb Haemost. 2006 Jan;4(1):137-47.

Castaman G, Federici AB, Bernardi M, Moroni B, Bertoncello K, Rodeghiero F.
Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective studycomparing patients with single (R1205H) and double (R1205H-M740I) defect.
J Thromb Haemost. 2006 Feb;4(2):357-60.

Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I.
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).
J Thromb Haemost. 2006 Apr;4(4):766-73.

Eikenboom J, Van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I.
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD.
J Thromb Haemost. 2006 Apr;4(4):774-82.

Federici AB, Santagostino E, Rumi MG, Russo A, Mancuso ME, Soffredini R, Mannucci PM, Colombo M.
The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study.
Haematologica. 2006 Apr;91(4):503-8.

Loffredo G, Baronciani L, Noris P, Menna F, Federici AB, Balduini CL.
Von Willebrand disease type 2B must be always considered in the differential diagnosis of genetic thrombocytopenias with giant platelets.
Platelets. 2006 May;17(3):149-52.

Lillicrap D, Nair SC, Srivastava A, Rodeghiero F, Pabinger I, Federici AB.
Laboratory issues in bleeding disorders.
Haemophilia. 2006 Jul;12 Suppl 3:68-75.

Federici AB, Castaman G, Thompson A, Berntorp E.
Von Willebrand's disease: clinical management.
Haemophilia. 2006 Jul;12 Suppl 3:152-8.

Federici AB.
Diagnosis of inherited von Willebrand disease: a clinical perspective.
Semin Thromb Hemost. 2006 Sep;32(6):555-65.

Federici AB.
Management of inherited von Willebrand disease in 2006.
Semin Thromb Hemost. 2006 Sep;32(6):616-20.

Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM.
Von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M. J Thromb Haemost. 2006 Sep;4(9):2088-90.

Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ.
Activation-independent platelet adhesion and aggregation under elevated shear stress.
Blood. 2006 Sep 15;108(6):1903-10.

Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB; Working Party on von Willebrand Disease Classification.
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.
J Thromb Haemost. 2006 Oct;4(10):2103-14.

Castaman G, Rodeghiero F, Tosetto A, Cappelletti A, Baudo F, Eikenboom JC, Federici AB, Lethagen S, Linari S, Lusher J, Nishino M, Petrini P, Srivastava A, Ungerstedt JS.
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study.
J Thromb Haemost. 2006 Oct;4(10):2164-9.

De Cristofaro R, Peyvandi F, Baronciani L, Palla R, Lavoretano S, Lombardi R, Di Stasio E, Federici AB, Mannucci PM.
Molecular mapping of the chloride-binding site in von Willebrand factor (VWF): energetics and conformational effects on the VWF/ADAMTS-13 interaction.
J Biol Chem. 2006 Oct 13;281(41):30400-11.

Federici AB, Berntorp E, Lee CA.
The 80th anniversary of von Willebrand's disease: history, management and research.
Haemophilia. 2006 Nov;12(6):563-72.

Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I.
Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).
Blood. 2007 Jan 1;109(1):112-21.
Erratum in: Blood. 2008 Mar 15;111(6):3299-300.

Federici AB, Mannucci PM.
Management of inherited von Willebrand disease in 2007.
Ann Med. 2007;39(5):346-58.

Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM.
Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease.
J Thromb Haemost. 2007 Feb;5(2):282-8.

Tosetto A, Rodeghiero F, Castaman G, Bernardi M, Bertoncello K, Goodeve A, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I.
Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD).
J Thromb Haemost. 2007 Apr;5(4):715-21.

Schneppenheim R, Castaman G, Federici AB, Kreuz W, Marschalek R, Oldenburg J, Oyen F, Budde U.
A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3.
J Thromb Haemost. 2007 Apr;5(4):722-8.

Piñol M, Sales M, Costa M, Tosetto A, Canciani MT, Federici AB.
Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease.
Haematologica. 2007 May;92(5):712-3.

Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM.
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
J Thromb Haemost. 2007 Jun;5(6):1115-24.

Federici AB, Castaman G, Franchini M, Morfini M, Zanon E, Coppola A, Tagliaferri A, Boeri E, Mazzucconi MG, Rossetti G, Mannucci PM.
Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients.
Haematologica. 2007 Jul;92(7):944-51.

Federici AB.
Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO.WILL Study.
Haemophilia. 2007 Dec;13 Suppl 5:15-24.

Federici AB, Mannucci PM, Marco P.
Von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report.
Haemophilia. 2008 Jan;14(1):133-9.

Federici AB.
The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
Haemophilia. 2008 Jan;14 Suppl 1:5-14.

Federici AB.
Update on the management of von Willebrand disease.
Clin Adv Hematol Oncol. 2008 Jan;6(1):29-30.

Federici AB.
Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?
J Thromb Haemost. 2008 Apr;6(4):565-8.

Goedert JJ, Scoppio BM, Pfeiffer R, Neve L, Federici AB, Long LR, Dolan BM, Brambati M, Bellinvia M, Lauria C, Preiss L, Boneschi V, Whitby D, Brambilla L.
Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial.
J Eur Acad Dermatol Venereol. 2008 Apr 1.

Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, Rodeghiero F.
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.
Blood. 2008 Apr 1;111(7):3531-9.

Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Pérez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I.
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD).
J Thromb Haemost. 2008 May;6(5):762-71.

Baronciani L, Federici AB, Castaman G, Punzo M, Mannucci PM.
Prevalence of type 2b 'Malmö/New York' von Willebrand disease in Italy: the role of von Willebrand factor gene conversion.
J Thromb Haemost. 2008 May;6(5):887-90.

Baronciani L, Federici AB, Cozzi G, La Marca S, Punzo M, Rubini V, Canciani MT, Mannucci PM.
Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von Willebrand factor in patients with type 3 von Willebrand disease.
Haemophilia. 2008 May;14(3):549-55.

Iorio A, Oliovecchio E, Morfini M, Mannucci PM; Association of Italian Hemophilia Centres Directors.
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis.
Haemophilia. 2008 May;14(3):444-53.

Franchini M, Gandini G, Giuffrida A, De Gironcoli M, Federici AB.
Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report.
Haemophilia. 2008 May;14(3):645-6.

Berntorp E, Archey W, Auerswald G, Federici AB, Franchini M, Knaub S, Kreuz W, Lethagen S, Mannucci PM, Pollmann H, Scharrer I, Hoots K.
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/Humate -P: history and clinical performance.
Eur J Haematol Suppl. 2008 May;(70):3-35.

Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR.
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
Blood. 2008 May 15;111(10):4979-85.

Collins P, Budde U, Rand JH, Federici AB, Kessler CM.
Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome.
Haemophilia. 2008 Jul;14 Suppl 3:49-55.

Federici AB.
Clinical and molecular markers of inherited von Willebrand disease type 3: are deletions of the VWF gene associated with alloantibodies to VWF?
J Thromb Haemost. 2008 Oct;6(10):1726-8.

Budde U, Federici AB, Goodeve A, Eikenboom J, Schneppenheim R.
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): reply to a rebuttal.
J Thromb Haemost. 2008 Nov;6(11):2002-3.

Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, Pecci A, Lenting PJ, De Groot PG.
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: A cohort study of 67 patients.
Blood. 2009 Jan 15;113(3):526-534